Stock comparison
Alnylam Pharmaceuticals
Eli Lilly
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
ALNY
Alnylam Pharmaceuticals
Market cap
$39.71B
Sector
Healthcare
LLY
Eli Lilly
Market cap
$1T
Sector
Healthcare
Overall winner
Eli Lilly LLY
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | ALNY | LLY | Winner |
|---|---|---|---|
| Warren Buffett | 58C | 72B | LLY |
| Benjamin Graham | 80D | 86A | LLY |
| Philip Fisher | 79B | 86A | LLY |
| Peter Lynch | 81A | 74B | ALNY |
| Joel Greenblatt | 63C | 78C | LLY |
| Charlie Munger | 75D | 85A | LLY |
| Terry Smith | 75B | 77C | LLY |
Side-by-side metrics
| Metric | ALNY | LLY |
|---|---|---|
| Market cap | $39.71B | $1T |
| P/E (TTM) | 66.1x | 36.6x |
| EV/EBIT | 75.5x | 34.1x |
| ROIC (TTM) | 19.66% | 32.06% |
| Gross margin | 80.89% | 83.51% |
| Net margin | 13.46% | 34.98% |
| Revenue CAGR 5y | 44.82% | 23.17% |
| EPS CAGR 5y | 38.42% | 40.81% |
| Debt / Equity | 1.2x | 1.4x |
| Dividend yield | 0.0% | 0.62% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
ALNY leads on
- Revenue CAGR 5y44.82%vs 23.17%+48%
- Debt / Equity1.2xvs 1.4x+15%
LLY leads on
- Dividend yield0.62%vs 0.0%+100%
- Market cap$1Tvs $39.71B+96%
- Net margin34.98%vs 13.46%+62%
- EV/EBIT34.1xvs 75.5x+55%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.